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Markov model with 3 stages: disease progression, disease free progression and
death in a time horizon of 3 years. Costs were based on direct medical costs of the
institution, drug administration costs and cost for the management of adverse
events and they are expressed in US dollars. RESULTS: The average treatment cost
for the alternatives were: $ 16,133.78 for XELOX, $ 25,690.58 for FOLFOX-4, $
27,686.35 for FOLFOX-6 and $ 21,904.12 for FOLFIRI. XELOX is the least costly alter-
native. The difference in costs ismainly due to the difference inmanagement costs
and the presence of grade 3-4 adverse events, mainly neutropenia. Based on clin-
ical trials, FOLFOX-6 presented neutropenia (47%), FOLFOX-4 (44%) and FOLFIRI
(26%), while the most severe adverse event was diarrhea with XELOX (12%). In the
disease management, FOLFOX-6, FOLOFX-4 and FOLFIRI require two hospitaliza-
tions per cycle for the application of the drug. Instead, XELOX requires only one
chemotherapy session. Since Capecitabine is orally administered, not only mini-
mizes the costs of administration, also has a better safety profile with less adverse
events. CONCLUSIONS: The use of Capecitabine combined with Oxaliplatin
scheme as first-line treatment of metastatic colorectal cancer, is the alternative
that minimizes costs to the health institutions, as well as improve quality of life
resulting from Capecitabine’s oral administration.
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OBJECTIVES: To identify which of the different chemotherapy alternatives minimizes
costs for the treatment of advanced and/or metastatic Gastric Cancer (GC) in Mexico.
METHODS: A cost minimization was performed considering the alternatives: EOX
(epirubicinoxaliplatincapecitabine), EOF (epirubicinoxaliplatinfluorouracil),
ECX (epirubicincisplatincapecitabine) and ECF (epirubicincisplatin fluorou-
racil) for the treatment of advanced and/ormetastatic gastric cancer (advGA) using
aMarkovmodel with 3 stages: progression, disease free progression and death. For
a time horizon of 3 years, it was taken into account direct medical costs for the
diseasemanagement, drug and its application cost, and costs incurred in theman-
agement of the associated adverse events. Costs are expressed in USD dollars.
RESULTS: ECXwas the alternativewith less costs ($6,293), followed by EOX ($7,692).
The chemotherapy combinations based on capecitabine proved to be the least
expensive. The alternative EOF had a cost of $10,904, while ECF was $9,873. The
factor that increased costs of EOF and ECF was the drug administration costs, as
they require to be administered as daily intravenous infusions in comparison of the
oral administration of capecitabine. Therefore, the administration costs of ECX and
EOX represent only 4.76% of the administration costs of ECF and EOF. The results of
the univariate sensitivity analysis confirmed savings with capecitabine versus ECF
from$5,721 to $6,209 and versus EOF from$5,691 to $6,178 in the totalmanagement
costs. The probabilistic analysis results also confirmed that in the ECF scheme
versus ECX, the combination with capecitabine is a cost-saving alternative. ECX
and EOX are alternatives that minimize costs at 100% of cases compared to ECF
and EOX respectively. CONCLUSIONS: The oral administration of capecitabine is
the factor that minimizes the cost of the alternatives in the chemotherapy combi-
nation schemes, also, the safety profile of capecitabine helps incurring in less costs
associated to the management of side adverse events.
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OBJECTIVES: CML is a clonal myeloproliferative neoplastic disorder characterized
by a reciprocal translocation between chromosomes 9 and 22, t(9;22)(q34;q11) lead-
ing to the formation of the BCR-ABL fusion gene.With the introduction of imatinib,
a BCR-ABL tyrosine kinase inhibitor (TKI), survival has improvedwith durable long-
term responses. Nilotinib is a more recently approved second generation TKI indi-
cated for treatment of CML as first- and second-line therapy. Shorter-term clinical
trials (24months) have shown that nilotinib produces a faster cytogenetic response
compared to imatinib, but long-term survival outcomes have not yet been reported
in clinical trials. The objective of this analysis is to explore the cost-effectiveness of
nilotinib compared to imatinib for the treatment of newly diagnosed CML in
chronic phase. METHODS: Using a healthcare payer perspective, a 72-month
Markov state transition model was developed in Microsoft Excel 2007. Major cyto-
genetic response, progression, and survival rates were obtained from a 24-month
head-to-head clinical trial and a 72-month single arm trial evaluating long-term
responses with imatinib. Nilotinib as a second-line therapy was allowed for pa-
tients who progressed while on imatinib. Drug costs were obtained from the Red
Book. Hospital and outpatient costs were obtained from reimbursement rates from
the Centers for Medicare and Medicaid Services. Sensitivity analyses were con-
ducted to test various assumptions. RESULTS: The base case analysis resulted in
0.1 life years gained for nilotinib compared to imatinib. Resultant quality-adjusted
life years (QALYs) for nilotinib and imatinib were estimated to be 4.39 and 4.23,
respectively. The additional cost for treating with nilotinib was $213,895, resulting
in an incremental cost effectiveness ratio (ICER) of greater than 1million dollars per
QALY saved. CONCLUSIONS: Based upon this analysis, the small additional sur-
vival benefits associated with nilotinib do not translate into a favorable ICER for
first-line treatment of CML in chronic phase.
PCN87
COST-EFFECTIVENESS OF HORMONE THERAPIES FOR ERWOMEN WITH
EARLY BREAST CANCER IN CANADA: EXPLORING THE POTENTIAL FOR THE
CYP2D6 GENETIC TEST
Djalalov S1, Beca J1, Li B2, Krahn M3, Hoch JS2
1St. Michael’s Hospital, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada,
3Toronto Health Economics and Technology Assessment (THETA) Collaborative, Toronto, ON,
Canada
BACKGROUND: Approximately 60% of breast cancer cases are hormone sensitive.
Tamoxifen is the most widely used treatment of hormone-dependent breast can-
cer. The pharmacological activity of tamoxifen is dependent on its conversion by
the hepatic drug-metabolizing enzyme CYP2D6. Patients with reduced CYP2D6
activity may derive inferior therapeutic benefit from tamoxifen, and may alterna-
tively be treated with newer aromatase inhibitors (AIs) sequentially or as mono-
therapy. However, the higher costs of AIs provide incentive for identifying patients
who will benefit from tamoxifen prior to treatment. OBJECTIVES: To evaluate the
cost-effectiveness of adjuvant mono and sequential hormone therapies, and
CYP2D6 testing in combination with tamoxifen mono and sequential (with AIs)
therapies for ER hormone sensitive women with early breast cancer in Canada.
METHODS:Weperformed a cost-effectiveness analysis using aMarkovmodel from
a societal perspectivewith a lifetime horizon. An embedded decision treewas used
to identify best treatment strategy according to CYP2D6 gene polymorphisms. Our
comparator is optimal treatment strategy without genetic testing. Patient popula-
tion is 65-year-old ER hormone sensitive women with early breast cancer. Ex-
pected value of perfect information was performed to identify future research
directions. Probabilistic sensitivity analysis was used to incorporate parameter
uncertainties. Outcomes were quality-adjusted life years (QALYs) and costs.
RESULTS: Our preliminary analysis suggested that the genetic testing and treat-
ment combination strategy were marginally more effective (0.005 QALY gained)
and cost CAD $102 more when compared to no testing (letrozole-tamoxifen se-
quential therapy). The incremental cost-effectiveness ratio (ICER) for the base case
was $21,732 per QALY. The results were sensitive to assumptions related to disease
progression,mortality rate and the drug cost. CONCLUSIONS: Themarginal gain in
effectiveness and extra cost may not warrant a recommendation for routine
CYP2D6 genetic testing in combination with tamoxifen monotherapy for ER
women with early breast cancer in the current setting.
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OBJECTIVES: The cost-effectiveness analysis compares plerixafor GCSF for stem
cell mobilization in Canada compared to using GSCF alone or GCSF  chemother-
apy in patients with multiple myelemo (MM) or non-Hodgkins’s lymphoma (NHL)
whose cellsmobilize poorly. NHL andMMare severe forms of hematological cancer
where autologous hematopoietic stem cell (HSC) transplantation is a standard of
care in Canada. In order to proceed to transplantation, a sufficient number of stem
cells need to be harvested during apheresis. Patients who collect 2 million HSCs
proceed to transplant. Those whose peripheral blood CD34 cell count on the day
before apheresis is below the range of 10 to 20 cells/uL is generally considered a
poor mobilizer. METHODS: The model uses a cohort semi-Markov process that
embeds two decision trees for autologous transplantation and continuation of
care. The Markov structure based on annual cycles consists of three health states -
Remission, Well and Death. The mobilization decision tree includes the pre-
apheresis, apheresis and transplant pathways. The continuation of care includes a
series of therapies currently used in Canadian clinical practice following failed
mobilization or relapse. Patients enter remission after successful transplantation
and continuation of care after unsuccessful transplantation. RESULTS: The results
showed that incremental cost-effectiveness ratio (ICER) for plerixafor  GCSF
verses GCSF alone was $19,191 for NHL and $60,835 for MM. When compared to
GCSF  chemo, the ICER was $14,330 for NHL and $31,622 for MM patients. Deter-
ministic sensitivity analysis was conducted to assess extreme values and model
uncertainty. Probabilistic sensitivity analysis was conducted to generate cost-ef-
fectiveness acceptability curves. Major data limitations include probability of suc-
cessful mobilization and number of apheresis days for GCSFchemo comparator.
CONCLUSIONS: The results show that plerixafor  GCSF, when used in the poor
mobilizer setting, is a cost-effective strategy for both NHL and MM patients in
Canada.
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OBJECTIVES: To identify the drug that offers the best pharmacoeconomic result for
the treatment of advanced or metastatic NSCLC previously treated with a chemo-
therapy regimen in public health institutions in Mexico. METHODS: It was devel-
oped a cost-utility analysis using a Markov model with monthly cycles in a time
horizon of 2 years. Themain output indicators were: Years of Quality Adjusted Life
(QALY’s) and total treatment cost per patient. The alternatives in the study were:
Erlotinib, Docetaxel and Pemetrexed. Costs are expressed in US dollars. RESULTS:
The average cost per patient for Erlotinib was $9,862, and $21,583 to $24,049 for
Docetaxel and Pemetrexed. Erlotinib provided 0.33 QALY’s, while Docetaxel pro-
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